Phase I Study of the Hedgehog Pathway Inhibitor IPI-926 in Adult Patients with Solid Tumors

    April 2013 in “ Clinical Cancer Research ”
    Antonio Jimeno, Glen J. Weiss, Wilson H. Miller … Charles M. Rudin
    Studysummary The study found that IPI-926 was well tolerated up to 160 mg once daily for 28-day cycles and showed activity as a single-agent treatment in Hedgehog pathway inhibitor-naïve patients with basal cell carcinoma.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on clincancerres.aacrjournals.org →
    Discuss this study in the Community →

    Research cited in this study 2

    1. Basal Cell Carcinomas in Mice Arise from Hair Follicle Stem Cells and Multiple Epithelial Progenitor Populations Journal of Clinical Investigation · 2011
    2. Modulation of Hair Growth with Small Molecule Agonists of the Hedgehog Signaling Pathway Journal of Investigative Dermatology · 2005